Procter & Gamble Health Ltd logo

Procter & Gamble Health Ltd

PGHL NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹9,599 Cr
Volatility
Low Risk
P/E Ratio
27.15
EBITDA
₹474 Cr
Return on Equity
62.32%
Debt to Equity
0.02
Book Value
₹316.01
EPS
₹128.93
52W High
₹6,975
52W Low
₹4,707

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Procter & Gamble Health Ltd insights

30 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 42.6%
  • Company has been maintaining a healthy dividend payout of 87.1%

Weaknesses

2
  • Stock is trading at 18.5 times its book value
  • The company has delivered a poor sales growth of 0.76% over past five years.

Growth Rate

Revenue Growth
50.91% ↗
Net Income Growth
39.46% ↗
Cash Flow Change
100.24% ↗
ROE
42.74% ↗
ROCE
42.50% ↗
EBITDA Margin (Avg.)
-4.43% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 42d ago
AI opinion · based on fundamentals
Risk medium

Procter & Gamble Health Ltd is a nearly debt-free healthcare company with a market cap of ₹10,447 Cr, trading at a PE of 32.3x and 20.1x book value. The company delivers exceptional return on equity (62% last year, 43% 3-year average) and maintains a dividend payout of 123%, but has historically struggled with revenue growth at just 0.76% CAGR over five years despite a recent TTM sales surge of 51%.

Bull Case 8
  • Virtually debt-free balance sheet provides financial resilience and flexibility for future investments
  • Exceptional ROE of 62% in the last year, with a 3-year average of 43% and 10-year average of 31%, indicating highly efficient capital deployment
  • Dividend payout ratio of 123% signals strong cash generation and shareholder-friendly capital allocation, with a current yield of 2.52%
  • TTM sales growth of 51% represents a significant acceleration from the 5-year CAGR of just 1%, suggesting a potential inflection point in revenue trajectory
  • TTM profit growth of 39% demonstrates operating leverage and margin expansion alongside the revenue surge
  • 3-year compounded profit growth of 19% materially outpaces 3-year sales growth of 8%, reflecting improving profitability and cost discipline
  • 10-year stock CAGR of 25% shows long-term wealth creation track record for patient investors
  • Backed by the global Procter & Gamble parentage, providing access to R&D, established brands, and operational best practices in healthcare
Bear Case 8
  • Stock trades at 20.1x book value, a steep premium that leaves little margin of safety if growth disappoints
  • 5-year compounded sales growth of only 0.76% indicates structural challenges in scaling revenue over extended periods
  • PE ratio of 32.3x is elevated for a company with a 5-year profit CAGR of just 5%, implying the market prices in growth not yet consistently delivered
  • 5-year stock CAGR of only 2% suggests prolonged periods of stagnant shareholder returns despite the high ROE
  • 10-year compounded sales growth of just 4% underscores limited top-line expansion in what should be a growing healthcare market
  • Dividend payout exceeding 100% at 123% means the company is returning more than it earns, which may not be sustainable long-term or limits reinvestment capacity
  • The sharp TTM sales jump of 51% may reflect one-time factors or base effects rather than sustainable organic growth, given the weak long-term track record
  • 1-year stock CAGR of 10% and 3-year CAGR of 7% lag broader market indices, indicating relative underperformance in recent periods

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 42d ago
Positives 2
  • Rs 45 dividend declared FY26 Jun 26

    P&G Health recommended a final dividend of Rs 45 per share for FY 2025-26, with tax document submission deadline of August 12, 2026.

  • INR 35cr productivity savings planned Jun 18

    P&G Health outlined its Q1FY26 strategy highlighting INR 35 crores in productivity savings and a 9% CAGR in the VMS (Vitamins, Minerals & Supplements) category.

Neutral 1
  • Senior management reshuffle from July Jun 25

    Key senior management changes effective July 1, 2026, including the appointment of Shine Matthew Sunny to a leadership role.

TL;DR: P&G Health is executing well with clear productivity targets (INR 35cr savings) and rewarding shareholders with a healthy Rs 45 dividend. No material headwinds are visible in recent news flow. The VMS category growing at 9% CAGR provides a strong secular tailwind. The management reshuffle bears watching but the overall trend remains stable to positive.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
301
305
310
252
284
313
310
311
339
325
374
370
364
Expenses
256
216
208
185
236
199
186
230
248
205
263
235
264
Operating Profit
45
89
102
67
48
114
123
81
90
120
110
136
100
OPM %
15%
29%
33%
27%
17%
36%
40%
26%
27%
37%
30%
37%
27%
Other Income
5
6
5
2
-18
3
4
3
4
5
4
4
36
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
6
6
7
7
7
6
6
5
5
6
6
6
6
PBT
44
88
100
63
23
111
122
79
89
119
109
133
129
Tax %
32%
26%
28%
26%
26%
26%
25%
22%
25%
26%
29%
29%
26%
Net Profit
30
66
72
47
17
82
91
61
66
89
78
95
96
EPS in Rs
17.96
39.5
43.42
28.05
10.11
49.6
54.76
36.86
39.87
53.34
46.74
56.99
57.92
Figures in ₹ Crores

Profit & Loss

  Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020 18mJun 2021Jun 2022Jun 2023Jun 2024Mar 2025 9mMar 2026TTM
Sales
940
993
698
849
927
1,356
1,009
1,114
1,230
1,151
934
1,408
1,433
Expenses
855
877
621
701
723
1,037
762
846
905
845
616
949
967
Operating Profit
85
116
77
148
204
319
246
268
325
307
319
459
466
OPM %
9%
12%
11%
17%
22%
24%
24%
24%
26%
27%
34%
33%
33%
Other Income
22
24
74
768
48
66
18
13
18
-5
10
15
49
Interest
0
0
0
0
0
0
1
0
1
1
0
1
1
Depreciation
23
25
19
21
17
29
30
27
28
27
17
24
24
PBT
83
115
132
895
234
355
233
253
314
273
312
450
490
Tax %
36%
31%
29%
6%
32%
28%
24%
24%
27%
26%
25%
27%
—
Net Profit
54
79
94
839
159
254
177
193
229
201
234
327
357
EPS in Rs
32.27
47.67
56.57
505
95.64
153
107
116
138
121
141
197
215
Div. Payout %
23%
23%
27%
87%
0%
150%
122%
45%
69%
215%
89%
104%
—
Figures in ₹ Crores

Balance Sheet

  Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025Mar 2026
Equity Capital
17
17
17
17
17
17
17
17
17
17
17
17
Reserves
575
647
717
1,524
800
890
687
600
734
522
520
508
Borrowings
0
0
0
0
0
0
8
3
12
10
8
9
Other Liabilities
192
215
258
219
250
269
275
269
338
247
250
308
Total Liabilities
784
879
991
1,759
1,067
1,176
986
888
1,101
794
794
841
Fixed Assets
132
111
115
104
101
101
104
112
144
128
116
102
CWIP
7
30
9
17
11
21
39
41
32
6
11
14
Investments
42
28
70
0
0
0
0
0
0
0
0
0
Other Assets
603
711
797
1,639
954
1,053
843
736
925
660
667
726
Total Assets
784
879
991
1,759
1,067
1,176
986
888
1,101
794
794
841
Figures in ₹ Crores

Cash Flow

  Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025Mar 2026
Operating
83
107
54
-130
—
235
247
170
236
228
169
338
Investing
-68
-75
-48
1,270
—
165
-32
-26
-22
-7
10
1
Financing
-12
-15
-22
-30
—
-883
-387
-289
-98
-418
-235
-344
Net Cash Flow
4
17
-16
1,109
—
-483
-172
-145
116
-197
-56
-5
Free Cash Flow
38
75
24
-157
—
212
196
132
198
207
168
323
CFO/OP
136
138
147
117
—
106
128
87
100
102
78
96
Figures in ₹ Crores

Ratios

  Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025Mar 2026
Debtor Days
49
39
64
28
30
26
22
27
34
27
57
43
Inventory Days
140
145
243
154
139
113
138
124
136
120
152
137
Days Payable
55
67
128
124
106
105
209
185
239
184
239
192
Cash Conversion Cycle
134
118
179
58
63
34
-49
-34
-69
-37
-30
-13
Working Capital Days
69
52
94
42
22
23
7
17
15
19
48
30
ROCE %
15%
18%
16%
78%
20%
29%
29%
38%
45%
45%
48%
84%

Shareholding Pattern

As of Jun 2026
Promoters 51.82%
Public 23.56%
DIIs 12.44%
FIIs 6.33%
Others 5.85%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
7.59%
6.24%
6.40%
6.61%
7.02%
6.87%
6.99%
7.24%
6.97%
6.20%
6.33%
DIIs
11.48%
11.81%
8.37%
8.53%
7.90%
8.07%
12.62%
12.43%
12.31%
12.30%
12.13%
12.67%
13.73%
14.55%
14.84%
14.71%
14.21%
14.16%
13.91%
13.84%
13.68%
12.44%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
24.58%
24.49%
24.80%
24.55%
24.81%
25.09%
24.46%
24.33%
24.09%
23.64%
23.43%
22.91%
22.61%
21.82%
21.46%
21.34%
21.90%
21.89%
22.15%
22.43%
23.17%
23.56%
Others
12.13%
11.88%
15.01%
15.10%
15.47%
15.02%
11.11%
11.43%
11.78%
12.25%
12.62%
5.02%
5.60%
5.41%
5.28%
5.12%
5.21%
5.14%
4.89%
4.94%
5.14%
5.85%
No. of Shareholders
0
53,075
58,818
63,525
65,537
66,289
65,729
65,148
61,030
58,856
57,919
56,730
56,778
55,923
54,792
53,736
53,993
52,478
50,006
49,302
50,883
49,056

Documents

Frequently Asked Questions about Procter & Gamble Health Ltd

What does Procter & Gamble Health Ltd do?
P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.[1]
Where is Procter & Gamble Health Ltd (PGHL) listed?
Procter & Gamble Health Ltd is listed on the Indian stock exchanges. It is listed on NSE: PGHL and BSE: 500126. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Procter & Gamble Health Ltd belong to?
Procter & Gamble Health Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd has a market capitalisation of approximately ₹9599.42 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Procter & Gamble Health Ltd?
The Price-to-Earnings (PE) ratio of Procter & Gamble Health Ltd is 27.15. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Procter & Gamble Health Ltd?
Over the past 52 weeks, Procter & Gamble Health Ltd has traded between a low of ₹4,707 and a high of ₹6,975. This range helps investors understand the stock's price volatility and recent trading levels.
Does Procter & Gamble Health Ltd pay dividends?
Yes, Procter & Gamble Health Ltd has a dividend yield of 3.51%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd has a Return on Equity (ROE) of 62.32%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Procter & Gamble Health Ltd on Tapetide?
On Tapetide, you can view Procter & Gamble Health Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.[1]

Website pghealthindia.com
CEO Mr. Milind Vasant Thatte M.B.A.
Employees 1,326
Listed 1996-04-24
Face Value ₹ 10
Issued Size 1,65,99,382

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List